The FDA just issued new enforcement guidance that could have a major impact on the ENDS and nicotine pouch marketplace. 

For years, retailers and distributors have been stuck in uncertainty: products with pending PMTAs were often treated the same as products with no regulatory filings at all. That created confusion for stores, wholesalers, manufacturers, and adult consumers. 

This new guidance gives the industry a clearer picture of where FDA says it intends to focus enforcement. 

 

 

And the key takeaway is this: 

FDA does not intend to prioritize enforcement against certain unauthorized ENDS and nicotine pouch products if they have pending PMTA applications that have been accepted and filed.  

 

What FDA Announced 

 

On May 8, 2026, FDA issued guidance titled “Enforcement Priorities for Certain New Tobacco Products Marketed Without Premarket Authorization.” 

The guidance applies to certain: 

• Electronic nicotine delivery systems, also known as ENDS  
• Nicotine pouch products  
• Products marketed without final FDA authorization  

FDA says it is focusing enforcement on the most serious categories: products with no PMTA, counterfeit products, misdeclared imports, deceptive products, and products tied to egregious conduct.  

 

Products FDA Says It Will Not Prioritize 

 

FDA states it does not intend to prioritize enforcement when a product has: 

• A pending PMTA that has been accepted and filed  
• A pending and accepted Supplemental PMTA  
• For non-tobacco flavored ENDS, an application FDA has determined includes data necessary to evaluate whether the product is appropriate for the protection of public health  

That last part matters. This does not mean every flavored product with a PMTA gets a free pass. FDA is saying the application must include the data needed for review. 

 

What This Means for B2B Buyers 

 

For wholesalers, distributors, and retailers, this guidance creates a more practical compliance framework. 

Products with real PMTA filings are now meaningfully different from products that never entered the FDA process. 

That matters when evaluating inventory, onboarding brands, and answering retailer questions. 

Retailers should be asking suppliers: 

• Does this product have a PMTA?  
• Has the application been accepted and filed?  
• Is there documentation available?  
• Is the product on FDA’s future public list?  
• Does the packaging avoid youth-appealing imagery?  
• Does the product have child-resistant packaging where required?  

 

What FDA May Still Target 

 

The guidance does not protect products with obvious compliance problems. 

FDA says it may still prioritize enforcement for products with underage-appealing features, including products that: 

• Use cartoon-like fictional characters  
• Disguise themselves as something other than a vape product  
• Resemble children’s toys, phones, or gaming devices  

FDA also says it may consider whether a product presents a greater public health or safety concern, including products with lack of required child-resistant packaging, or fire-hazard risks.  

 

FDA Will Create a Public List 

 

One of the biggest developments is FDA’s plan to create and maintain a public list of products that fall within this enforcement policy. 

That list is designed to give consumers and retailers more transparency about which products FDA does not intend to prioritize for enforcement under the guidance.  

Manufacturers who want to be listed should contact their FDA regulatory health project manager or email: 

CTP_enforcementpriorities@fda.hhs.gov 

 

Important: This Is Not FDA Authorization 

 

Retailers need to understand the difference between enforcement discretion and marketing authorization. 

FDA makes clear that falling under this enforcement policy does not mean a product is likely to receive final authorization.  

In plain English: 

Pending PMTA status may lower enforcement priority, but it does not equal approval. 

 

Why This Guidance Matters 

 

This is a significant shift for the legal nicotine marketplace. 

It recognizes that products with pending FDA applications should not be treated the same as products that never attempted compliance. 

For responsible manufacturers, wholesalers, and retailers, this gives the supply chain a clearer path forward. 

For bad actors, counterfeiters, and companies with no PMTA filings, FDA is signaling that enforcement pressure is not going away. 

 

Bottom Line for Retailers 

 

If you sell ENDS or nicotine pouches, now is the time to tighten your compliance checklist. 

Work with suppliers that can document PMTA status, avoid youth-appealing packaging, and provide clear product information. 

The market is not “anything goes.” 

But FDA’s new guidance suggests that products with legitimate pending applications may have a more stable path while the agency continues its scientific review process.